Exudative AMD Risk Following Blue Light-Filtering IOL Implantation: A Population-Based Study According to Non-Exudative AMD Status.

Am J Ophthalmol

From the Department of Ophthalmology (J.Y.K., J.C., J.S.L, C.S.L., S.H.B., S.S.K., Y.J.K), Institute of Vision Research, College of Medicine, Yonsei University, Severance Hospital, Seoul, Republic of Korea. Electronic address:

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To evaluate whether blue light-filtering (BLF) intraocular lenses (IOLs) reduce the risk of exudative age-related macular degeneration (AMD).

Design: A nationwide, population-based cohort study using data from the Korean National Health Insurance Sharing Service (NHISS) database.

Participants: Individuals who underwent cataract surgery and received the same type of IOL (BLF or clear) in both eyes within one year between January 2012 and December 2018.

Methods: Participants were categorized into BLF IOL or clear IOL groups, and the risk of exudative AMD was compared between the 2 groups. The 10-year cumulative incidence of exudative AMD was estimated using Kaplan-Meier analysis. Cox proportional hazard models and the Fine-Gray model were applied to calculate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs), adjusting for age, sex, socioeconomic status, and systemic diseases. The same analysis was performed in the cohort matched by age, sex, and the calendar year of the index date.

Main Outcome Measures: 10-year cumulative incidence, incidence rate, and HR for exudative AMD.

Results: A total of 21,741 individuals with BLF IOLs were compared to 56,357 individuals with clear IOLs. The mean follow-up duration was 7.0 ± 2.5 years in the BLF IOL group and 6.7 ± 2.5 years in the clear IOL group (P = .069). The 10-year cumulative incidence of exudative AMD was 1.8% (95% CI, 1.5%-2.0%) in the BLF IOL group and 1.7% (95% CI, 1.5%-1.8%) in the clear IOL group. The incidence rates per 100,000 person-years were 162.8 and 153.9 in the BLF IOL group and clear IOL groups, respectively, with no significant difference in the adjusted Cox model (aHR 1.12; 95% CI, 0.96-1.30; P = .149) and the Fine-Gray model (aHR 1.15; 95% CI, 0.97-1.36; P = .120). Subgroup analyses based on age, sex, and history of nonexudative AMD showed no protective effect of BLF IOLs, with comparable incidence rates across all subgroups. Similar results were observed in the matched cohort analysis.

Conclusions: BLF IOL implantation in cataract surgery does not reduce the risk of developing exudative AMD in the South Korean population, regardless of a history of nonexudative AMD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2025.07.007DOI Listing

Publication Analysis

Top Keywords

exudative amd
20
blf iol
20
iol group
20
clear iol
16
10-year cumulative
12
cumulative incidence
12
age sex
12
iol
11
blf
9
blue light-filtering
8

Similar Publications

Purpose: To report on the real-world experience of using intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD).

Design: Retrospective interventional case series.

Methods: Eyes with symptomatic GA secondary to AMD were treated with 15mg of intravitreal pegcetacoplan and participated in an ongoing prospective swept-source optical coherence tomography angiography (SS-OCTA) imaging study.

View Article and Find Full Text PDF

ObjectiveTo evaluate the efficacy of switching from anti-vascular endothelial growth factor (VEGF) to faricimab in reducing exudative signs in age-related macular degeneration (AMD) patients receiving regular injections (every 8 weeks or less) without restarting a standard induction regimen.MethodsThis retrospective, observational, multicenter study included patients with exudative AMD previously treated with aflibercept 2 mg or ranibizumab every ≤8 weeks and switched to faricimab while maintaining their previous injection interval. The first follow-up visit occured after switching to faricimab, with a single injection, and corresponded to the pre-existing injection interval.

View Article and Find Full Text PDF

Objective: To evaluate the association between antidepressant use and the risk of developing non-exudative and exudative age-related macular degeneration (AMD), as well as the progression from non-exudative to exudative AMD, in patients using selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCAs).

Design: Retrospective clinical cohort study.

Subjects: Patients aged ≥40 years identified from the TriNetX database (October 2004-October 2023).

View Article and Find Full Text PDF

The retinal pigment epithelium (RPE) is a pigmented monolayer of cells beneath the neural retina that supports photoreceptor cell function essential for vision. Our study explores the diversity of adult human RPE subpopulations and associated implications for retinal biology. Employing cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), we identified distinct RPE cell subpopulations characterized by unique single-cell transcriptomic and surface protein signatures.

View Article and Find Full Text PDF

Background: There is increasing evidence that vascular disease and chronic perfusion deficits play a role in the progression of age-related macular degeneration (AMD). This controlled clinical study evaluated the safety and feasibility of treating patients with late-stage AMD and associated geographic atrophy (GA). In addition, exploratory endpoints evaluated the potential to disrupt the disease process and initiate functional changes.

View Article and Find Full Text PDF